Study to Evaluate Monotherapy and Combination Immunotherapies in Participants With PD-L1 Positive Non-small Cell Lung Cancer
Trial details
- Registry ID
- NCT04262856
- Phase
- Phase 2
Drug identity checked against registry records
Also recorded as AB122
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| Study to Evaluate Monotherapy and Combination Immunotherapies in Participants With PD-L1 Positive Non-small Cell Lung CancerNCT04262856 | RCUS | Phase 2 | Completed | 2025-07-09Actual |
| Study Evaluating Effectiveness and Safety of Zimberelimab and Domvanalimab in Lung CancerNCT04736173 | RCUS | Phase 2 | Completed | 2026-09-17Actual |
| A Clinical Trial of a New Combination Treatment, Domvanalimab and Zimberelimab, Plus Chemotherapy, for People With an Upper Gastrointestinal Tract Cancer That Cannot be Removed With Surgery That Has Spread to Other Parts of the BodyNCT05568095 | RCUS | Phase 3 | Completed | 2026-08-28Actual |
| A Safety and Efficacy Study of Treatment Combinations With and Without Chemotherapy in Adult Participants With Advanced Upper Gastrointestinal Tract MalignanciesNCT05329766 | RCUS | Phase 2 | Completed | 2026-09-07Actual |
| No regulatory events match this view.This does not mean no FDA events have occurred. |